Shanghai Drugmaker Gets Green Light for Cutting-Edge Cancer Treatment

TRENDING: ByteDance Targets July Launch of Upgraded AI Video Model; Embodied AI Startup Kunlunxing Lands Multibillion Yuan Raise; Europe Has a Lot to Learn From China About Electric Trucks, Volvo CTO Says

LATEST: Europe Has a Lot to Learn From China About Electric Trucks, Volvo CTO Says; Embodied AI Startup Kunlunxing Lands Multibillion Yuan Raise; ByteDance Targets July Launch of Upgraded AI Video Model; China’s Starlink Challenger Seeks Up to $2.2 Billion for Satellite Network Push; New Model Propels Zhipu AI’s Market Value to Record HK$1 Trillion; In AI Pitch, Alibaba Chairman Urges Europe to Look Beyond U.S. Tech; Cover Story: China’s AI Boom Is Rewiring Its Power Grid; In Depth: How AI Is Rewiring White-Collar Work in China; Chipmaker YMTC Cedes Control of Foundry Unit Ahead of Mega IPO; Chinese Startup Manifold AI Raises Fresh Funding as Investors Bet on ‘World Models’; Crealights Takes Step Closer to Hong Kong IPO as Data Center Boom Fuels Growth Prospects; Tencent Lets AI Agent Make Purchases Through WeChat Pay; Galaxea AI Chief Says China Could Lead Robotics Models Within Three Years; SiliconFlow Raises $294 Million as China’s AI Inference Demand Surges; Ant Revamps Alipay With AI Assistant in Biggest App Overhaul; New Model Sends Zhipu AI’s Stock Soaring; DJI, Insta360 File Competing U.S. Patent Lawsuits Over Camera Tech; Cover Story: When Employees Leave, Their AI Clones Carry on Working; AI Stocks Zhipu, MiniMax Slide as Lock-Up Expirations Near; Japan’s Chip Exports to China Surge as Bilateral Trade Rebounds

By Tang Ziyi / Dec 18, 2018 05:09 PM / Business & Tech

Photo: VCG

A Shanghai drugmaker has won approval to launch a cutting-edge cancer therapy in China, becoming the first domestic firm to compete with two American rivals in the novel PD-1 cancer-treatment space.

Shanghai Junshi Biosciences received the green light from China’s National Medicine Products Administration on Monday, the regulator said.

The injectable drug belongs to a group of biology-based cancer treatments known as PD-1 inhibitors, shorthand for programmed cell death protein 1 inhibitor, which uses a patient’s own immune system to destroy cancer cells.

China is one of the world’s largest markets for cancer treatments. In 2016, sales of anti-cancer drugs in China reached 102 billion yuan ($14.9 billion), accounting for 18% of the global market, according to market research firm IMS.

Beauty Salon Scam Convinced Customers to Pay 1 Billion Yuan for Fake Cancer Drugs

Money-Losing Cancer Drugmaker Looks for Funding With Hong Kong IPO

Novartis Bets on Beijing Approving Cutting-Edge Cancer Treatment

Share this article

Open WeChat and scan the QR code